Advantis Medical Imaging makes medical imaging more accessible, user-friendly and data-driven by merging it with cloud technology in order to make a real impact for healthcare organizations and their patients. Established in 2016 by Zoi Giavri, Paris Ziogkas and Dimitrios Rozakis, Advantis’ mission is to improve the detection efficiency of severe human pathologies such as brain tumor, Alzheimer's, Multiple Sclerosis and ALS through the development of advanced web-based software solutions that solve the problems of current software applications used for analysis & processing of medical images. The company is based in Athens and Eindhoven, while planning to expand to the US within 2020.
Advantis has developed Brainance MD, a pure web-based neuroimaging software application which enables the display, review and processing of brain MRI exams. Advantis targets three different brain MRI exams and provides a highly advanced browser-based software solution with state-of-the-art scientific methodologies, achieving highly reliable results in an intuitive user interface. Brainance MD demonstrates a mix of competitive advantages ranging from highly reliable results, ease of access, high time optimization plus better economics, flexible recurring pricing plans, pure in-browser usage, collaborative processing and responsive remote technical support. Brainance MD has so far been purchased by healthcare organizations such as hospitals and diagnostics centers within EU. Brainance MD is a CE Marked medical device and Advantis is an ISO 13485 certified medical device manufacturer.
Advantis has raised more than 1.2M EUR so far and is growing its teams in Athens and Eindhoven. The company is expanding its presence within EU as a growing number of healthcare organizations is adopting its innovative and user-friendly neuroimaging platform towards the optimization of their clinical and research medical image diagnostic workflows. Recently Advantis completed a post-seed round lead by Metavallon VC to accelerate its business expansion within EU and also continue its R&D roadmap on the basis of two pillars; automation and feature enhancement of its current products and expansion to further human organs.